QPS is the main sponsor of the Analytical and Bioanalytical Day at the 7th World ADC Meeting, February 20 – 22, 2017 at the Maritim proArte Hotel in Berlin this week. Over 300 enthusiasts are expected to attend. Our Director of Biologics/Mass Spectrometry, Dr. Fabrizia Fusetti, gave a presentation on a multidisciplinary approach for bioanalysis …
QPS Is Eastern Minority Supplier Development Council (EMSDC) 2016 Class IV Supplier of the Year
For outstanding performance including growth in sales, continuous growth in minority business to minority business purchases, innovation in the delivery of services, significant and continuous contribution to the growth and development of our community, and commitment to the cause and success of the EMSDC, QPS has been named Class IV Supplier of the Year! The …
QPS Assay Finder Database Grows 47 New Assays!
For all you assay aficionados out there, we thought you’d be juiced to know — we just added a whopping 47 new assays to the QPS Assay Finder Database: Agomelatine; Albendazole + metabolite; Amphetamine; Apixaban; Apremilast; Atazanavir; Atorvastatin + metabolites; Bosutinib; Bupropion + metabolites; Caffeine + metabolites; Carbamazepine + metabolite; Cetirizine; Chlorzoxazone; Colchicine; Dexamethasone; Dolutegravir; …
Sanjay Mitter new VP and Global Head of Clinical Research Services
Mr. Sanjay Mitter joined QPS as VP and Global Head of Clinical Research Services. He is currently responsible for Clinical Research, i.e. global pharmacokinetics, data management, biostatistics, medical writing and publishing. He also oversees clinical monitoring and project management in the US. Sanjay comes to us fresh from a stint as Global Director of Biostatistics, …
Let’s Talk Neuro at the AAIC 2016 in Toronto, Canada, July 24-27, 2016
Join us from July 24-27, 2016 in Toronto, Canada for the Alzheimer’s Association International Conference. QPS neuroscientists will attend the AAIC 2016 and would be pleased to meet you there at our booth#207 to discuss potential and ongoing projects. QPS posters presented: Sunday, July 24, 2016, 9:30 AM to 10:30 AM (Session: P1-02-062, Poster: #12005) …
QPS Netherlands scientist Daniel Wilffert nominated for New Investigator Award by Bioanalysis Zone!
Since 2012, a New Investigator Award has been given annually to honor excellence among bioanalytical scientists within their first five years in the industry. In this regard, Daniel Wilffert, a 2016 award nominee from QPS Netherlands, is truly fresh off the starting blocks. He started @QPS Holdings LLC last August and only just defended his …
Ben Chien is an EY Entrepreneur Of The Year® 2016 Finalist for Greater Philadelphia!
QPS CEO Ben Chien has made it through to the round of 30 (31, actually) being considered for this year’s prestigious EY Entrepreneur Of The Year Award for the Greater Philadelphia area. The only competitive awards program in the world for entrepreneurs and leaders of high-growth companies, the 30 year-old program operates in 145 cities …
Another CRO Leadership Award! For Compatibility, Expertise, Quality and Reliability
Each year, Life Science Leader honors CROs that are the top performers in Compatibility, Capabilities, Expertise, Quality, and Reliability. To determine the winners, the magazine teams up with Industry Standard Research (ISR). ISR looks at 27 different performance metrics, as rated by decision-making executives at biopharmaceutical companies. “Real customers provide experiential feedback on their involvement …
QPS’ Patient Recruitment Management at the 2016 Annual Meeting of the Clinical Trials Community in Israel
Patient recruitment is one of the most critical foundations of any clinical trial. Effective patient recruitment sets the trial down a path toward success if done well, or can create a road full of potholes if managed incorrectly. On April 11th, Barbara Derler, PhD, heading the EU patient recruitment team from the QPS site in …
QPS Global Clinical Operations Team Aces Enrollment for a Global Study of a Prostate Cancer Drug
QPS has been assisting an international Sponsor to perform a global, late-phase study to investigate the safety, efficacy, and pharmacokinetic behavior of an investigational drug in subjects with advanced prostate carcinoma. The original enrollment goal was 133 patients to be enrolled in approximately 18 months. The QPS Global Clinical Operations team enrolled 137 patients at …